KARACHI: Sanofi announced the introduction of its next generation basal insulin (insulin glargine U300) in Pakistan at a scientific event attended by leading doctors. The control of blood sugar levels in patients with diabetes remains suboptimal. Sanofi’s new basal insulin, designed to act over 24 hours, seeks to address this unmet need. This basal insulin was approved by FDA in 2015 and since then the drug has been introduced in many countries, including the US, Canada, Russia, Japan and India. Sanofi’s insulin glargine U300 works like the human body’s natural insulin and helps control blood sugar, along with diet and exercise. The new insulin promises stable blood sugar control throughout the day and night. Sanofi Pakistan Country Chair and General Manager Asim Jamal said, “We have been empowering people living with diabetes in Pakistan for over 50 years through oral therapies and for over a decade with insulin therapies. It is our endeavor to bring innovative solutions to patients to improve their health.”
Published in The Express Tribune, January 26th, 2019.
Like Business on Facebook, follow @TribuneBiz on Twitter to stay informed and join in the conversation.
Comments are moderated and generally will be posted if they are on-topic and not abusive.
For more information, please see our Comments FAQ